<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02673697</url>
  </required_header>
  <id_info>
    <org_study_id>TPS003</org_study_id>
    <nct_id>NCT02673697</nct_id>
  </id_info>
  <brief_title>Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement</brief_title>
  <acronym>PERSIST-AVR</acronym>
  <official_title>Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement A Controlled Randomized Trial in the Surgical Treatment of Aortic Valve Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LivaNova</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LivaNova</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized, stratified non blinded multi-center, international, post market
      trial assessed in a non-inferiority study.

      A minimum of 1234 subjects will be enrolled at approximately 60 worldwide investigational
      sites where the device is commercially available.

      The primary objective of this trial is to test the safety and efficacy of Perceval versus
      standard sutured stented bioprosthetic aortic valves among the intended trial population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PERSIST-AVR is designed to collect data on sutureless valve (Perceval sutureless aortic heart
      valve), a new type of biological aortic valve, comparing data with standard biological aortic
      valve, considered the gold standard for aortic valve replacement. This prospective,
      randomized international multicenter study is planned to demonstrate, as primary endpoint,
      the non inferiority of Major Adverse Cardiac and Cerebrovascular (MACCE) events at one year
      while showing superiority in resource consumptions at hospital discharge in patients treated
      with Perceval valve when compared to standard aortic valve replacement. The study is planned
      to cover the lack of prospective, randomized comparison data between sutureless valve and
      standard aortic biological sutured valve. To achieve the primary endpoint, 1234 patients will
      be recruited in 60 worldwide investigational sites. The be part of the trial, investigational
      sites should have demonstrated experience with the implantation of the Perceval and able to
      implement the requirements of the study protocol.. All subjects with severe symptomatic
      aortic stenosis or steno-insufficiency who are candidates for surgical replacement of their
      native aortic valve according to established guidelines in current medical practice and as
      specified in the Perceval valve Instruction for Use (IFU) are the intended population for
      inclusion in this randomized trial. The patients will be followed for 5 years after the
      implant, the total duration of study including the enrollment time will be 7 years
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 22, 2016</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from MACCE</measure>
    <time_frame>1 year post-operatively</time_frame>
    <description>The primary endpoint is freedom from MACCE (composite endpoint of all cause death, myocardial infarction, stroke, and valve re-intervention) at one year based on Clinical Event Committee (CEC) adjudication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgical times</measure>
    <time_frame>Intra-operative</time_frame>
    <description>Cross clamp time during index procedure
Cardiopulmonary bypass time during index procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalized Consumption Index</measure>
    <time_frame>Hospital Discharge (average 10 days)</time_frame>
    <description>Normalized Consumption Index including resource consumption items such as (but not limited to):
Operative room time,
Duration of ICU and total hospital stay
Incidence of specific serious adverse events as defined in Appendix 3
Blood transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduced Normalized Consumption Index</measure>
    <time_frame>Hospital Discharge (average 10 days)</time_frame>
    <description>Reduced Normalized Consumption Index, including resource consumption items such as (but not limited to):
Operative room time,
Duration of ICU and total hospital stay
Incidence of specific serious adverse events as defined in Appendix 3
Blood transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire</measure>
    <time_frame>At 1 month and 1 year post surgery</time_frame>
    <description>Questionnaire for quality of life (EQ5D)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraprocedural and periprocedural serious adverse events regardless of relationship with the device</measure>
    <time_frame>72 hours post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All valve and procedure relevant serious adverse events as specified in Valve Academic Research Consortium-2 (VARC-2) guidelines</measure>
    <time_frame>At 30 days and annually up to 5 years post surgery</time_frame>
    <description>Early safety at 30 days
Clinical efficacy after 30 days
Time related valve safety: [Structural Valve Deterioration (SVD), endocarditis, Thrombosis, Thromboembolic events (excluding stroke), and bleeding] annually up to 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious device related adverse events</measure>
    <time_frame>Up to 5 years post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from MACCE</measure>
    <time_frame>At 2, 3, 4 and 5 years post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Pacemaker implantation</measure>
    <time_frame>Up to 1 year post surgery</time_frame>
    <description>The rate of pacemaker implantation during the first year post surgery will be analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic endpoints (site-reported data)</measure>
    <time_frame>Preoperatively, at hospital discharge (average 10 days), between 1-3 month, 1 year, 3 year and 5 years post surgery</time_frame>
    <description>Performance of the valve in terms of hemodynamic behavior</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic endpoints in a reduced cohort of patients assessed by core lab</measure>
    <time_frame>Preoperatively, at hospital discharge (average 10 days), between 1-3 month, 1 year, 3 year and 5 years post surgery</time_frame>
    <description>Performance of the valve in terms of hemodynamic behavior.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1234</enrollment>
  <condition>Aortic Valve Disease</condition>
  <condition>Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Perceval</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Perceval sutureless aortic heart valve (Perceval valve) is a bioprosthesis manufactured with bovine pericardium and assembled on a Nitinol stent. The Perceval valve is designed to offer an alternative to surgically implanted flexible prostheses (stented and stentless biological valves). A special feature of the device is that it is self-anchoring and does not require sutures to be fixed to the implant site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>other Stented biological valves</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The comparator will be other commercially approved standard biological sutured stented valves, both bovine and porcine. The choice of the comparator tissue valve will be at the discretion of the participating investigators.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Perceval valve</intervention_name>
    <description>Sutureless Aortic Biological Valve</description>
    <arm_group_label>Perceval</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>other stented biological valve</intervention_name>
    <description>Any biological stented valves available on the market (Edwards, Medtronic, St.Jude, LivaNova, Labcor)</description>
    <arm_group_label>other Stented biological valves</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject has an indication for treatment by valve replacement with a bioprosthesis
             according to the IFU, through either full sternotomy or mini-sternotomy.

          2. The subject has aortic valve disease that can be treated with a commercially available
             Perceval valve size, based on preoperative CT-scan.

          3. The subject has:

               1. critical aortic valve area defined as an initial aortic valve area of ≤1.0 cm2 or
                  aortic valve area index &lt; 0.6 cm2/m2 AND

               2. Mean gradient &gt; 40 mmHg or Vmax &gt; 4 m/sec by resting echocardiogram or
                  simultaneous pressure recordings at cardiac catheterization [or with dobutamine
                  stress, if subject has a left ventricular ejection fraction (LVEF) &lt;55%] or
                  velocity ratio &lt; 0.25;

          4. The subject is symptomatic due to aortic stenosis with functional class of New York
             Heart Association (NYHA) II or higher.

          5. The subject has signed the informed consent.

          6. The subject is of legal minimum age.

          7. The subject will be available for postoperative follow-up beyond one year.

        Exclusion Criteria:

          1. The subject has a contraindication for treatment by the Perceval valve or by a
             bioprosthetic aortic valve as stated in the IFU.

          2. The subject has aneurismal dilation or dissection of the ascending aortic wall.

          3. The subject is scheduled for concomitant procedures other than Coronary Aortic Bypass
             Graft (CABG), myectomy with or without aortic annulus enlargement

          4. The subject has congenital bicuspid (i.e. Sievers type 0) or unicuspid aortic valve.

          5. Anatomical structures not suitable for Perceval valve such as: aortic root
             enlargement, where the ratio between the diameter of the sino-tubular junction and the
             annulus diameter is &gt; 1.3.

          6. The subject has a prosthetic heart valve in any position, including mitral valve
             repair.

          7. The subject has a stroke or myocardial infarction (STEMI and NSTEMI) within 30 days
             prior to the planned valve implant surgery.

          8. The subject has active endocarditis, myocarditis, or sepsis.

          9. The subject is in cardiogenic shock manifested by low cardiac output and needing
             hemodynamic support.

         10. The subject is allergic to nickel alloys.

         11. The subject is already included in another clinical trial that could confound the
             results of this clinical investigation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theodor Fischlein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Nurnberg, Nurnberg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto Lorusso, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Royal Melbourn</name>
      <address>
        <city>Parkville VIC</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Abteilung fuer Herzchirurgie</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Hietzing</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Antwerp</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Univ. Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>2H234</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southlake Regional Health Centre</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. de Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital privé de Bois Bernard</name>
      <address>
        <city>Bois Bernard</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. de Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz- und Gefäß-Klinik</name>
      <address>
        <city>Bad Neustadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Dresden GmbH Universitätsklinik</name>
      <address>
        <city>Dresden</city>
        <zip>1307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASKLEPIOS Klinikum Harburg</name>
      <address>
        <city>Hamburg</city>
        <zip>D- 21075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Heart Center Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg</name>
      <address>
        <city>Nürnberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gottsegen Hungarian Institute os Cardiology</name>
      <address>
        <city>Budapest</city>
        <zip>H-1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Poliambulanza Istituto Ospedaliero</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Cuore Morgagni Pedara</name>
      <address>
        <city>Pedara</city>
        <state>CT</state>
        <zip>95030</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>lstituto Clinico Sant'Ambrogio e San Siro</name>
      <address>
        <city>Milan</city>
        <state>MI</state>
        <zip>20149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Toscana Gabriele Monasterio-Presidio Ospedaliero di Massa</name>
      <address>
        <city>Massa</city>
        <state>MS</state>
        <zip>54100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale SS. Annunziata</name>
      <address>
        <city>Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Carlo Poma</name>
      <address>
        <city>Mantova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht University Hospital</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polisano European Hospital</name>
      <address>
        <city>Sibiu</city>
        <zip>550172</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario De A Coruña</name>
      <address>
        <city>A Coruna</city>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital University Germans Trias I Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Virgen De La Arrixaca</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara University Cebeci Education and Research Hospitals</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marmara University</name>
      <address>
        <city>Istanbul</city>
        <zip>34722</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Victoria Hospital</name>
      <address>
        <city>Blackpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>January 21, 2016</study_first_submitted>
  <study_first_submitted_qc>February 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2016</study_first_posted>
  <last_update_submitted>October 23, 2018</last_update_submitted>
  <last_update_submitted_qc>October 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sutureless valve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

